Q1 Earnings Estimate for Insmed Issued By HC Wainwright

Insmed Incorporated (NASDAQ:INSM) – HC Wainwright issued their Q1 2025 EPS estimates for Insmed in a research report issued on Friday, February 21st. HC Wainwright analyst A. Fein anticipates that the biopharmaceutical company will post earnings of ($1.47) per share for the quarter. HC Wainwright has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. Stifel Nicolaus dropped their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Wells Fargo & Company raised their price target on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Royal Bank of Canada began coverage on shares of Insmed in a research note on Tuesday. They issued an “outperform” rating and a $100.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus target price of $91.60.

Insmed Trading Down 3.2 %

INSM stock opened at $77.50 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The company’s 50-day simple moving average is $74.43 and its 200 day simple moving average is $73.67. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a market capitalization of $13.86 billion, a PE ratio of -13.86 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million.

Institutional Trading of Insmed

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after purchasing an additional 1,075,796 shares during the period. Darwin Global Management Ltd. raised its position in Insmed by 23.5% during the 4th quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after purchasing an additional 2,463,261 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock valued at $877,113,000 after purchasing an additional 123,429 shares in the last quarter. Capital International Investors raised its position in Insmed by 9.1% during the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after purchasing an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Insmed by 7.2% during the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after purchasing an additional 273,759 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This trade represents a 3.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 2,978 shares of Insmed stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the sale, the chief executive officer now directly owns 392,589 shares in the company, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 532,207 shares of company stock valued at $41,400,465. Insiders own 4.60% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.